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Abstract
Objective To evaluate the clinical benefit of lipid lowering drug
treatment in patients with and without diabetes mellitus, for
primary and secondary prevention.
Design Systematic review and meta-analysis.
Data sources Cochrane, Medline, Embase, and reference lists
up to April 2004.
Study selection Randomised, placebo controlled, double blind
trials with a follow-up of at least three years that evaluated lipid
lowering drug treatment in patients with and without diabetes
mellitus.
Data extraction Two independent reviewers extracted data. The
primary outcome was major coronary events defined as
coronary heart disease death, non-fatal myocardial infarction,
or myocardial revascularisation procedures.
Results Twelve studies were included. Lipid lowering drug
treatment was found to be at least as effective in diabetic
patients as in non-diabetic patients. In primary prevention, the
risk reduction for major coronary events was 21% (95%
confidence interval 11% to 30%; P < 0.0001) in diabetic patients
and 23% (12% to 33%; P = 0.0003) in non-diabetic patients. In
secondary prevention, the corresponding risk reductions were
21% (10% to 31%; P = 0.0005) and 23% (19% to 26%;
P ≤ 0.00001). However, the absolute risk difference was three
times higher in secondary prevention. When results were
adjusted for baseline risk, diabetic patients benefited more in
both primary and secondary prevention. Blood lipids were
reduced to a similar degree in both groups.
Conclusions The evidence that lipid lowering drug treatment
(especially statins) significantly reduce cardiovascular risk in
diabetic and non-diabetic patients is strong and suggests that
diabetic patients benefit more, in both primary and secondary
prevention. Future research should define the threshold for
treatment of these patients and the desired target lipid
concentrations, especially for primary prevention.
Introduction
The prevalence of diabetes mellitus is increasing. Up to 218 mil-
lion people are likely to have the disease by 2010.1 The current
understanding is that type 2 diabetes mellitus is a metabolic dis-
order, defined by hyperglycaemia, with dyslipidaemia, hyperten-
sion, abdominal obesity, and insulin resistance. The management
of diabetes mellitus has changed recently, from a focus on hyper-
glycaemia alone to a multifactorial approach to risk manage-
ment.1
The risk of myocardial infarction in patients with diabetes
mellitus without a history of myocardial infarction is as high as
that in patients without diabetes mellitus who have had a
myocardial infarction.2 Mortality after the first myocardial infarc-
tion is higher in both men and women with diabetes mellitus
than in their non-diabetic counterparts.3 US epidemiological
data show that although mortality due to coronary artery disease
has declined overall, this is not the case in the diabetic
population. In the UK prospective diabetes study,4 49% of deaths
within 10 years of diagnosis were due to cardiovascular disease.
In addition, atherosclerosis is more frequent and more extensive
and has an earlier onset among people with diabetes mellitus
than in people without the condition.
Diabetes affects virtually all lipids and lipoproteins, and dysli-
pidaemia is a consistent finding in people with type 2 diabetes.
Patients typically have increased plasma concentrations of
triglycerides, low plasma concentrations of high density lipopro-
tein (HDL) cholesterol, but only slightly raised plasma
concentrations of low density lipoprotein (LDL) cholesterol.
Patients with type 2 diabetes also tend to have a preponderance
of atherogenic small dense LDL.5–8 In one study, 79% of patients
were classified as having small dense LDL (apolipoprotein B in
LDL-5 plus LDL-6 > 25 mg/dl).9
The effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (statins) in treating dyslipidaemia, and
thereby reducing the risk of coronary events, has been shown in
large scale studies of both primary and secondary intervention
to reduce coronary artery disease.10 The results of the heart pro-
tection study did not show a threshold effect in benefit associated
with reduction in LDL cholesterol,11 suggesting that the use of
the classic target concentration to guide treatment may result in
undertreatment of many patients who would benefit from addi-
tional lowering of LDL cholesterol. The National Cholesterol
Education Program Adult Treatment Panel III guidelines include
diabetes mellitus in the newly defined coronary artery disease
risk equivalent category, carrying the recommendation of lipid
lowering treatment to reduce LDL cholesterol to a target of
< 100 mg/dl.12
A recent meta-analysis has evaluated the efficacy of lipid low-
ering drug treatment in patients with type 2 diabetes on the basis
of subgroup analysis from large trials and showed that both stat-
ins and fibrates reduce the cardiovascular risk.13 These data
served as a basis for the background paper that the American
College of Physicians used to support the recent guidelines for
lipid control in the management of type 2 diabetes.14 The main
practice recommendations were that lipid lowering drug
treatment should be used for secondary prevention of cardiovas-
cular mortality and morbidity in all patients (both men and
women) with known coronary artery disease and type 2 diabetes
and that statins should be used for primary prevention against
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macrovascular complications in patients (both men and women)
with type 2 diabetes and other cardiovascular risk factors.
Bearing in mind the limitations of this meta-analysis (search
date, number of included trials, outcomes selected, and data for
non-diabetic patients), we aimed to evaluate and compare the
efficacy of lipid lowering drug treatment in patients with and
without diabetes mellitus, by doing a meta-analysis of published
unconfounded randomised, prospective, placebo controlled,
double blind clinical trials.
Methods
Studies
The criteria for inclusion of trials in the meta-analysis were a
lipid lowering/cholesterol drug arm; a placebo arm; adequate
concealment of random allocation; double blind assessment,
including clinical outcomes; at least 500 patients per group; ref-
erence to type 2 diabetic patients and non-diabetic patients in
both arms; follow-up of at least three years; a hard end point that
was a cardiovascular event as the primary or secondary end
point; and provision for or allowing calculation of individual
results for the diabetic and non-diabetic subgroups.
We considered trials that enrolled patients with or without
previous coronary artery disease, aiming to evaluate the efficacy
in both primary and secondary prevention. We excluded trials
that followed patients for a short period of time, mainly because
cardiovascular risk falls relatively little within the first two years
before the full effect of reducing serum LDL cholesterol concen-
trations is achieved,15 thereby underestimating the preventive
effect of lipid lowering drug treatment.16
Outcome measures
Our primary outcome was a composite of major coronary events
defined as coronary artery disease death, non-fatal myocardial
infarction, or myocardial revascularisation procedures (coronary
artery bypass grafting or percutaneous transluminal coronary
angioplasty). Secondary outcomes were coronary artery disease
death or non-fatal myocardial infarction, coronary artery disease
death, non-fatal myocardial infarction, revascularisation proce-
dures, stroke, and blood lipid concentration changes: total
cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides.
Search strategy for identification of studies
We identified published studies through a literature search using
Medline (1966 through April 2004), Embase (1980 through
April 2004), and Cochrane Central (in Cochrane Library issue 2,
2004) and by extensive searching using cross references from
original articles and reviews.
The search of the electronic databases used the following
terms: exp “antilipemic agents”/; lovastatin; simvastatin; fluvasta-
tin; pravastatin; cerivastatin; atorvastatin; rosuvastatin; bezafi-
brate; colestipol; gemfibrozil; procetofen; or nicotinic acid. We
searched all terms as indexed and as free text terms. Additionally,
we used the conditions (exp “diabetes mellitus”/or diabet*.tw)
and (exp “cardiovascular diseases”/or “cerebrovascular
disorders”/; or “mortality”/or “myocardial revascularization”/)
to identify trials that included diabetic patients and measured
cardiac or cerebrovascular outcomes. We limited the search to
English language papers and to humans. We screened titles, key-
words, and abstracts of the citations downloaded from the
electronic searches and obtained full copies of potentially
suitable reports for further assessment.
Study selection and data extraction
Two authors (JC, MB) independently assessed the studies identi-
fied by the search strategy, to identify potentially suitable trials
according to the criteria outlined above. Details about methodo-
logical quality and sources of bias, demographics, and clinical
characteristics, number of patients excluded or lost to follow-up,
definition of outcomes, entry and exclusion criteria, and extrac-
tion of eligible data were obtained independently, written on to
standardised forms, and cross checked for accuracy. All disagree-
ments were resolved by consensus.
Data analyses
We used the statistical software provided by the Cochrane
Collaboration (Revman 4.2.7) for statistical analyses. We tested
heterogeneity between trial results by using the I2 test. We
reported the results as relative risk reduction (and 95%
confidence intervals), using the DerSimonian and Laird random
effect method or the Mantel-Hansel fixed effect method, accord-
ing to the existence or not of important heterogeneity between
trial results.
We compared the significance of any differences between
subgroups by calculating a two tailed z score
(z = (lnOR1 − lnOR2)/√(var[lnOR1]+var[lnOR2 ]), where OR1
and OR2 are the combined odds ratios from each subgroup and
var is the variance of each determined from the 95% confidence
interval).17 We also used the standard 2 test for heterogeneity.18
We calculated the number needed to treat and 95%
confidence interval from meta-analysis estimates (adjusted odds
ratio) and did not treat the data as if they all arose from a single
trial, as this approach is more prone to bias, especially when
important imbalances exist between groups within one or more
trials in the meta-analysis.19 Calculations also took into account
the baseline risk, defined as the percentage of patients with
events in the control arm.
Analysis was done separately for primary and secondary pre-




The search yielded a total of 581 reports. Applying our criteria,
we selected 12 trials for inclusion in the final analysis; six trials
reported data on primary coronary artery disease prevention,
and eight reported on secondary prevention.11 20–37 Table 1 shows
the main characteristics of these studies.
We excluded two important trials (WOSCOPS and BIP)
because no data were available for diabetic patients. WOSCOPS
was a primary prevention trial of pravastatin versus placebo that
enrolled 6595 male patients with hypercholesterolaemia, of
whom only 1% had diabetes.38 39 The relative risk reduction of
coronary events was 31% (95% confidence interval 17% to 43%).
BIP was a secondary prevention trial of bezafibrate versus
placebo that enrolled 3090 patients, of whom only 10% had dia-
betes.40 No significant differences were found.
Event rate
As expected, diabetic patients had a significantly higher risk of
major coronary events than non-diabetic patients, in both
placebo and treatment groups, in primary and secondary
prevention trials (fig 1 and fig 2).
Clinical outcomes
Lipid lowering drug treatment seems to be equally efficacious in
diabetic and non-diabetic patients. In primary prevention, the
risk reduction for a major coronary event was 21% (11% to 30%;
P < 0.0001) in diabetic patients and 23% (12% to 33%;
P = 0.0003) in non-diabetic patients treated with either statins or
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gemfibrozil. In secondary prevention, the risk reduction for a
major coronary event was 21% (10% to 31%; P = 0.0005) in dia-
betic patients and 23% (19% to 26%; P < 0.00001) in
non-diabetic patients treated with either statins or gemfibrozil.
Table 1 Characteristics of included studies
Trial
Type of
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LIPS33 Secondary Successful PCI Fluvastatin 40 mg
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Post-CABG34,35 Secondary Coronary bypass
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outcomes
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mg twice a day
2 531 64 (?-74)
(77% >60)
0 30 4.5 5.1** CHD death or
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5
CHD=coronary heart disease; CVD=cerebrovascular disease; DM=diabetes mellitus; HDL-C=high density lipoprotein cholesterol; LDL-C=low density lipoprotein cholesterol; total-C=total cholesterol
MI=myocardial infarction; HT=hypertension; PAD=peripheral arterial disease; PCI=percutaneous coronary intervention.
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Fig 1 Event rate for major coronary events in primary prevention trials (mean















1.53 (1.44 to 1.62)
Hazard ratio
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Non-diabetic Diabetic Non-diabetic
Fig 2 Event rate for major coronary events in secondary prevention trials (mean
weighted follow-up 5.1 years)
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Although we found similar relative risk reductions and odds
ratios for the primary outcome in primary and secondary
prevention, the absolute risk difference was significantly higher
in secondary prevention. In primary prevention, the risk
difference for major coronary events was − 0.02 ( − 0.04 to
− 0.00; P = 0.1) in diabetic patients and − 0.02 ( − 0.02 to − 0.01;
P < 0.00001) in non-diabetic patients (fig 3). In secondary
prevention, the risk difference for major coronary events was
− 0.07 ( − 0.11 to − 0.03; P = 0.0003) in diabetic patients and
− 0.05 ( − 0.06 to − 0.04; P < 0.00001) in non-diabetic patients
(fig 4).
In secondary prevention, we found important differences in
secondary outcomes between diabetic and non-diabetic patients.
The risk reduction in diabetic and non-diabetic patients treated
with either statins or gemfibrozil was 22% (9% to 34%; P = 0.001)
and 26% (22% to 30%; P < 0.00001) for coronary artery disease
death or non-fatal myocardial infarction; 30% (8% to 47%;
P = 0.01) and 21% (5% to 35%; P = 0.01) for coronary artery dis-
ease death (fig 5); 39% (4% to 62%; P = 0.03) and 29% (18% to
39%; P < 0.00001) for non-fatal myocardial infarction (fig 6);
30% (17% to 41%; P ≤ 0.0001) and 23% (18% to 27%;
P ≤ 0.00001) for revascularisation procedures (fig 7); and 36%
(17% to 51%; P = 0.0008) and 22% (13% to 30%; P ≤ 0.00001) for
stroke (fig 8).
Although the efficacy of lipid lowering drug treatment,
assessed by risk reduction, was in general similar in diabetic and
non-diabetic patients, when we adjusted the results for baseline
risk diabetic patients benefited more than non-diabetic patients
in secondary prevention for coronary artery disease death, non-
fatal myocardial infarction, revascularisation, and stroke. This
difference did not reach significance for primary prevention of
major coronary events. Table 2 shows the number needed to
treat and the benefit per 1000 patients treated.
For some outcomes we found significant heterogeneity
(I2 > 50%) between study results. This was the case for primary
prevention of major coronary events in non-diabetic patients
(I2 = 68%)—the funnel plot showed that this was because of the
results of the ALLHAT-LLT and PROSPER studies—and in sec-
Diabetic patients
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Total (95% CI)
Total events: 433 (treatment), 543 (placebo)
Test for heterogeneity: χ2=6.46, df=5, P=0.26, I 2=22.6%
Test for overall effect: z=3.93, P<0.0001
Non-diabetic patients







Total events: 920 (treatment), 1167 (placebo)
Active group: any statin or gemfibrozil
 HHS
Subtotal (95% CI)
Total events: 54 (treatment), 76 (placebo)
Total (95% CI)
Total events: 974 (treatment), 1243 (placebo)
Test for heterogeneity: χ2=13.97, df=5, P=0.02, I 2=64.2%
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Fig 3 Primary prevention of major coronary events
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ondary prevention of major coronary events in diabetic patients
(I2 = 54%), owing to the results of the PROSPER study. Addition-
ally, in secondary prevention of coronary artery disease death
(I2 = 63%) and non-fatal myocardial infarction in non-diabetic
patients (I2 = 51%) it was because of the results of the post-CABG
study, and in secondary prevention of non-fatal myocardial
infarction in diabetic patients (I2 = 54%) it was owing to the
results of the CARE study (see figures 3 to 6 for individual study
results). As we have taken trials’ heterogeneity into account in the
analysis, our results probably underestimate the true magnitude
of the treatment effect.
Effects on blood lipids
The magnitude of change in blood lipids was similar in diabetic
and non-diabetic groups; most trials showed a decrease of
15-20% in total cholesterol and increases of 5-7.5% in HDL cho-
lesterol (fig 9). Trials that used gemfibrozil (VA-HIT and HHS)
showed smaller decreases in total cholesterol and LDL
cholesterol. In the VA-HIT trial, no changes in LDL cholesterol
were detected in either group.
Discussion
High blood cholesterol has been shown to be a risk factor for
cardiovascular death and coronary heart disease in patients with
or without a history of coronary artery disease.41 42 As the
relation between blood cholesterol and cardiovascular risk is
continuous43 (although it can be J shaped for total mortality in
some studies), no definite threshold exists above which patients
must be treated. In fact, the decision to treat depends more on
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Test for heterogeneity: χ2=14.82, df=7, P=0.04, I 2=52.8%
Test for overall effect: z=3.48, P=0.0005
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Fig 4 Secondary prevention of major coronary events
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the expected absolute risk reduction, taking into account the
amount of resources that can be diverted for prevention.44 Con-
sequently, variable entry criteria are found in several clinical tri-
als.
Cardiovascular disease is the most common cause of death in
the general population. In the United Kingdom and United
States, 60-70% of the population die from cardiovascular disease.
In people with diabetes, cardiovascular disease complications
cause even more morbidity and mortality.45 Diabetes is an
independent risk factor for cardiovascular disease (up to
fivefold), and as many as 80% of patients with type 2 diabetes die
from cardiovascular complications, a risk that is not completely
explained by traditional risk factors.46
Our meta-analysis clearly confirms that reduction of LDL
cholesterol concentrations results in an important decrease in
major coronary events in diabetic patients and shows similar
relative risk reductions and odds ratios for our primary
outcomes (major coronary events) in both diabetic and
non-diabetic patients and in primary and secondary prevention.
However, the absolute risk difference was three times higher in
secondary prevention, reflecting the higher baseline cardiovas-
cular risk of these patients, as indicated by the higher rate of
coronary events in secondary prevention trials.
We were unable to analyse secondary outcomes in primary
prevention, as no data were available from the trials. Also,
indirect comparisons between statins and fibrates should be
made with caution, as only one trial evaluated fibrate treatment.
Importantly, the results of some secondary outcomes in second-
ary prevention clearly show that diabetic patients benefit signifi-
cantly more from treatment with lipid lowering drugs than do
non-diabetic patients.
Limitations of the study
Our meta-analysis has some limitations. Firstly, we included the
results of the PROSPER, post-CABG, and VA-HIT studies in our
primary outcome, although these studies report only combined
results for coronary events and stroke. Secondly, for all our sec-
ondary outcomes we excluded the data from diabetic patients in
the HPS study, because only 33% of these patients had history of
coronary artery disease and no individual information was avail-
able for subgroups of diabetic patients with or without previous
coronary artery disease. Thirdly, the definition of diabetes has
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Total (95% CI)
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Test for heterogeneity: χ2=2.60, df=3, P=0.46, I 2=0%
Test for overall effect: z=2.58, P=0.01
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Fig 5 Secondary prevention of coronary heart disease death
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changed over the years and seven (4S, HHS, VA-HIT,
post-CABG, LIPID, HPS, and CARE) of the 12 studies included
have released post hoc analysis for the diabetic patients’
subgroup (for the meta-analysis we considered the most updated
results and not those from the original reports). Fourthly, we
included the post-CABG study, which had a 2x2 factorial design
and compared moderate versus aggressive treatment without a
true placebo arm. Fifthly, we were unable to explore the effect of
the dose or individual drugs. None the less, to our knowledge,
this is the first meta-analysis that has compared cardiovascular
risk reduction in diabetic versus non-diabetic patients.
Implications for practice
Although the benefits of statins for secondary prevention of
coronary artery disease have been well documented, they are not
being optimally used in patients at higher risk—the ones most
likely to benefit. A recent cohort study of 396 077 patients aged
66 years or more who had a history of cardiovascular disease or
diabetes mellitus found that only 19.1% of the patients were pre-
scribed statins. Additionally, the likelihood of statin use
diminished progressively as baseline cardiovascular risk and
future probability of death increased.47
The management of dyslipidaemia in adults with diabetes is
receiving attention, as these patients are at higher risk of
coronary artery disease and statins could have a preferential
effect to decrease concentrations of atherogenic small dense
LDL, which could provide an antiatherogenic effect greater than
that expected from effects on LDL cholesterol and triglycerides
alone. However, large, prospective, randomised outcome trials
designed for diabetic patients that have studied the efficacy of
lipid lowering drug treatment are lacking. The angiographic dia-
betes atherosclerosis intervention study (DAIS) was the first of
the lipid intervention studies specifically designed for diabetes
mellitus; fenofibrate resulted in 42% less increase in stenosis
compared with placebo, as assessed by quantitative coronary
arteriography.48 This was an angiographic study that enrolled
418 diabetic patients and combined those with and without pre-
existing clinical coronary disease.
The collaborative atorvastatin diabetes study (CARDS) has
recently been published.49 We excluded this study from our
analysis, because it did not fulfil our inclusion criteria (there was
no subgroup of non-diabetic patients). However, given the
importance of this trial, we did a sensitivity analysis by including
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Fig 6 Secondary prevention of non-fatal myocardial infarction
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it in the meta-analysis and found a similar risk reduction for
major coronary event in primary prevention for diabetic
patients: 23% (14% to 31%; P < 0.00001) versus 21% (11% to
30%; P < 0.0001) without CARDS. The number needed to treat
was the same when we include the results of the CARDS: 37 (25
to 69) versus 37 (24 to 75) without CARDS.
Although strong data support the efficacy and safety of stat-
ins for primary prevention in patients with diabetes mellitus,
some controversy still exists about their use in patients with a low
risk of coronary disease.50 These ongoing studies will provide the
prospective outcome data that are needed for the optimal man-
agement of diabetic patients.
Future research should clearly define the threshold over
which diabetic patients must be treated and the blood
cholesterol target, especially in primary prevention. Until these
data are available, we think that our results support the use of
statins not only for secondary prevention but also for primary
prevention in these patients.
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Fig 7 Secondary prevention of myocardial revascularisation procedures (coronary artery bypass grafting or percutaneous transluminal coronary angioplasty)
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Fig 8 Secondary prevention of stroke
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Secondary prevention
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Fig 9 Change in blood lipid concentrations. HDL-C=high density lipoprotein
cholesterol; LDL-C=low density lipoprotein cholesterol (no data for total
cholesterol were available in VA-HIT)
What is already known on this topic
Cardiovascular disease is the most common cause of death
in the general population and causes even greater
morbidity and mortality in people with type 2 diabetes
The effectiveness of lipid lowering drugs in reducing the
risk of coronary events has been shown in large scale
studies of both primary and secondary prevention
Large randomised outcome trials designed specifically for
diabetic patients are lacking
What this study adds
Meta-analysis of published trials showed that patients with
diabetes benefit more than non-diabetic patients, in both
primary and secondary prevention
This may have important clinical implications, particularly
for primary prevention in patients with type 2 diabetes
Amendment
This is version 2 of the paper. Table 1 has minor changes, and
the graphics in figure 2 have been revised to accord with the
numbers given. These changes do not alter the conclusions of
the article.
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